169 S/F94 as a proxy for COVID-19 severity 7 Measure Distribution/ Event rate Estimated treatment effect Total n (β = 80% 2p = 0.05) S/F94 day 5 Mean = 2.83 SD = 1.47 ρ vs Day 0 = 0.56 Δ S/F94: 0.173 1,552 S/F94 day 8 Mean = 3.15 SD = 1.57 ρ vs Day 0 = 0.46 Δ S/F94: 0.150 2.692 WHO day 5 4: 5,242/14,004 5: 2,903/14,004 6: 3,091/14,004 7: 385/14,004 8: 1,198/14,004 9: 438/14,004 10: 747/14,004 Proportional odds ratio: 0.84 3,504 WHO day 8 4: 5,562/11,881 5: 1,880/11,881 6: 1,688/11,881 7: 455/11,881 8: 1,037/11,881 9: 370/11,881 10: 889/11,881 Proportional odds ratio: 0.84 3,527 1-level sustained improvement 14,556/47,260 (30.8%) Risk ratio: 1.03 6,061 2-level sustained improvement 5,860/47,260 (12.4%) Risk ratio: 1.04 2,959 28-day mortality 10,811/69,464 (15.6%) Risk ratio: 0.85 7,267 Supplementary Table 3. Comparison of outcome measures among 69,464 hospitalised patients aged 20-75. The estimated treatment effect is for a 15% relative reduction in mortality. For S/F94, the mean, standard deviation (SD) and correlation with S/F94 on day 0 are reported for both day 5 and day 8. For the WHO ordinal severity scale, the number of people in each category between 4 (hospitalised, no oxygen support) and 10 (dead) are reported. For 1- and 2-level sustained improvement, the number of people reaching sustained improvement is reported. For 28-day mortality, the proportion of patients who died at day 28 is reported. Sample sizes shows the total number of subjects needed in both arms using a 1:1 allocation.
RkJQdWJsaXNoZXIy MTk4NDMw